This year’s Drugs to Watch™ report from Clarivate™ will spotlight 13 drugs set to make a mark in 2024, including those expected to reach blockbuster status as well as those with the potential to transform treatment paradigms and serve unmet patient needs.
We also explore key topics shaping the marketplace such as the rise of gene editing and AI/ML-derived therapeutics, the impact of the Inflation Reduction Act on drug innovation, the maturation of the biosimilars marketplace, and how real world data is enabling clinical trials and more.
Interested in learning more about Drugs to Watch? Ahead of the 2024 release, explore recent insights below.
Access global intelligence, advanced analytics and global experts from Clarivate.